US00650F1093 - Common Stock
ADAPTIVE BIOTECHNOLOGIES
NASDAQ:ADPT (5/8/2024, 9:06:06 AM)
3.3905
+0.28 (+9.02%)
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 790 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).
ADAPTIVE BIOTECHNOLOGIES
1165 Eastlake Ave E
Seattle WASHINGTON 98102
P: 12066590067
CEO: Chad Robins
Employees: 790
Website: https://www.adaptivebiotech.com
ADPT stock results show that Adaptive Biotechnologies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...
Announces CFO transition
Announces CFO transition...
Here you can normally see the latest stock twits on ADPT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: